2022
Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2021
Geographic Access to Radiation Therapy Facilities in the United States
Maroongroge S, Wallington D, Taylor P, Zhu D, Guadagnolo B, Smith B, Yu J, Ballas L. Geographic Access to Radiation Therapy Facilities in the United States. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 600-610. PMID: 34762972, DOI: 10.1016/j.ijrobp.2021.10.144.Peer-Reviewed Original ResearchConceptsRadiation therapyRT facilitiesGeographic accessOlder median ageRadiation therapy facilitiesMeasures of geographic accessU.S. populationMedian ageRT accessZIP Code Tabulation AreasState purposesLogistic regressionTherapy facilitiesHigher incomeLinear acceleratorPercentage pointsImprove accessPopulation-level measuresUnited States
2020
Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy And Oncology 2020, 148: 235-242. PMID: 32505965, DOI: 10.1016/j.radonc.2020.04.037.Peer-Reviewed Original ResearchConceptsConventionally fractionated radiation therapyHypofractionated radiation therapyUltrahypofractionated radiation therapyLate grade 2Radiation therapyGrade 2Weighted random effects meta-analysesSummary effect sizesLocalized prostate cancerCompare treatment modalitiesDerSimonian and Laird methodPhase III protocolsRandom-effects meta-analysesGenitourinary toxicityEffects meta-analysesGastrointestinal toxicityProspective trialsMedian ageProstate cancerTreatment modalitiesComparing patientsIII protocolLaird methodTherapyMeta-analysisAssociation of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaCytoreductive nephrectomyICI eraImproved overall survivalNational Cancer DatabaseOverall survivalIFN eraFuhrman gradeBenefit of CNEfficacy of ICIsClinical T stageCox regression analysisTreatment facility typeRenal cell carcinomaCARMENA trialInterferon eraMultivariable associateN0 diseaseOS benefitProspective reevaluationMedian ageT stageCell carcinomaCancer DatabasePartial nephrectomy
2016
Genomic predictors of biochemical failure following radical prostatectomy.
Aneja S, Yu J, Glazer P. Genomic predictors of biochemical failure following radical prostatectomy. Journal Of Clinical Oncology 2016, 34: 114-114. DOI: 10.1200/jco.2016.34.2_suppl.114.Peer-Reviewed Original ResearchPathologic T stageGleason 7 diseaseBiochemical failureRadical prostatectomyT stageProstate adenocarcinomaClinical dataPredictors of BFAggressive regional therapyClinical patient characteristicsPre-treatment PSARNA expressionStratification of patientsHierarchical logistic regression modelsLogistic regression modelsMedian followAggressive therapyPatient characteristicsCancer Genome AtlasExpression of TP53Gleason 7Median ageRegional therapyGleason scoreClinical correlates